Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Infectious Uveitis of the Posterior Segment of the Eye Clear all
Completed Phase 3 Interventional Results available

Study Assessing Double-masked Uveitis Treatment

NCT01358266
View directory record Official record
Conditions
Uveitis; Posterior, Disorder
Interventions
DE-109 44 ug, DE-109 440 ug, DE-109 880 ug
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Results available

Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

NCT00543296
View directory record Official record
Conditions
Uveitis
Interventions
0.59 mg Fluocinolone Acetonide implant
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jul 23, 2026, 10:59 AM EDT
Recruiting Phase 3 Interventional

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

NCT05486468
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
Interventions
Yutiq 0.18 MG Drug Implant, Sham Injection
Drug · Other
Lead sponsor
Texas Retina Associates
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 23, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

NCT05070728
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Intermediate
Interventions
Sham Injector, FAI Insert
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI insert, Sham injection
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program

NCT02251938
View directory record Official record
Conditions
Non-Infectious Uveitis of the Posterior Segment of the Eye
Interventions
DE-109 440 μg
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Phoenix, Arizona • Sacramento, California • Golden, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

NCT00407082
View directory record Official record
Conditions
Noninfectious Posterior Uveitis
Interventions
fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Jul 23, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional Results available

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

NCT03711929
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

NCT02748512
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 23, 2026, 10:59 AM EDT
Active, not recruiting Phase 4 Interventional

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Fullerton, California • Glendale, California • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 23, 2026, 10:59 AM EDT